| Drospirenone with 17beta-estradiol in the postmenopausal woman with hypertension. | |
| | |
MedLine Citation:
|
PMID: 17364595 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Hypertension is one of the most important risk factors for the development of cardiovascular disease. The prevalence of hypertension increases with age and also after the menopause; therefore, blood pressure monitoring and effective control of elevated blood pressure are very important in postmenopausal women. The knowledge that aldosterone is a dual cardiovascular and endocrine hormone has blurred the once distinct boundary between gynecology and cardiovascular medicine. Aldosterone plays a major role in salt and water homeostasis, but also binds to mineralocorticoid receptors in the cardiovascular system, leading to structural and functional changes and consequent organ damage. Highly selective aldosterone blockade via the mineralocorticoid receptor has long-term antihypertensive effects. Drospirenone is a novel progestogen with aldosterone receptor antagonism (PARA), and therefore has antihypertensive effects through reduced salt and water retention. A new hormone therapy that combines 17beta-estradiol with drospirenone has been shown in several clinical studies to have a blood pressure-lowering effect in postmenopausal women with elevated blood pressure, in addition to effectively relieving symptoms of the menopause. These findings suggest a potential additional benefit on the cardiovascular system for the drospirenone/17beta-estradiol combination in the treatment of women with menopausal symptoms and elevated blood pressure. |
| | |
Authors:
|
W B White |
Related Documents
:
|
7894215 - Evidence for cardiovascular remodeling in a patient with bartter's syndrome. 16333235 - Nesiritide: past, present, and future. 7032815 - Blood pressure and the renin--angiotensin--aldosterone system. 3258645 - Urinary excretion of aldosterone metabolite kelly-m1 in patients with adrenal dysfunction. 17785625 - Change in salt intake affects blood pressure of chimpanzees: implications for human pop... 12757575 - Paradoxical vasodilation during lower body negative pressure in patients with vasodepre... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Climacteric : the journal of the International Menopause Society Volume: 10 Suppl 1 ISSN: 1369-7137 ISO Abbreviation: Climacteric Publication Date: 2007 Feb |
Date Detail:
|
Created Date: 2007-03-16 Completed Date: 2007-05-01 Revised Date: 2011-12-23 |
Medline Journal Info:
|
Nlm Unique ID: 9810959 Medline TA: Climacteric Country: United States |
Other Details:
|
Languages: eng Pagination: 25-31 Citation Subset: IM |
Affiliation:
|
Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut Health Center, Farmington, Connecticut 06030, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Androstenes
/
therapeutic use* Antihypertensive Agents / therapeutic use* Blood Pressure / drug effects Drug Combinations Estradiol / therapeutic use* Estrogen Replacement Therapy* Female Humans Hypertension / drug therapy* Postmenopause |
| Chemical | |
Reg. No./Substance:
|
0/Androstenes; 0/Antihypertensive Agents; 0/Drug Combinations; 0/estradiol-drospirenone combination; 50-28-2/Estradiol |
| Comments/Corrections | |
Comment In:
|
Climacteric. 2011 Dec;14(6):607-8
[PMID:
22085236
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Menopause and cardiovascular disease: the evidence.
Next Document: Effects of blood pressure reduction on cardiovascular risk estimates in hypertensive postmenopausal ...